𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of temozolomide plus pegylated interferon-α-2b for metastatic melanoma

✍ Scribed by Wen-Jen Hwu; Katherine S. Panageas; Jennifer H. Menell; Lynne A. Lamb; Suzan Aird; Susan E. Krown; Linda J. Williams; Paul B. Chapman; Philip O. Livingston; Jedd D. Wolchok; Alan N. Houghton

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
100 KB
Volume
106
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Temozolomide in combination with interfe
Temozolomide in combination with interferon α-2b in patients with metastatic melanoma : A Phase I dose-escalation study
✍ Sanjiv S. Agarwala; John M. Kirkwood 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## BACKGROUND Metastatic melanoma (MM) is associated with a high risk of central nervous system (CNS) metastases, and current chemotherapy does not adequately treat or protect patients with MM against CNS metastases. Therefore, the authors initiated a Phase I study to determine the pha

A Phase II study of “decrescendo” interl
A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy
✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH